Trial Profile
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2023 Results assessing safety and efficacy of the combination of olaparib and ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma, published in the British Journal of Cancer.
- 01 Jul 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 01 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.